At the news
? NEUTRALIMPACT 5/10 PRESS-RELEASE filed Nov 2, 2026 at 08:00 ET
Chemomab Therapeutics announced that the SEC declared effective the S-4 registration statement for its proposed merger with Scipher Medicine Corporation. A special shareholder meeting to vote on the merger is scheduled for December 4, 2026, with closing expected in early 2027. Upon closing, pre-merger Chemomab equity holders will own approximately 32% of the combined company and will receive contingent value rights tied to nebokitug milestones.
- SEC declared effective the S-4 registration statement for the Chemomab/Scipher merger on October 30, 2026.
- Special meeting of Chemomab shareholders to vote on the merger is scheduled for December 4, 2026.
- Closing expected in early 2027, subject to shareholder approval, redomiciling to the U.S., and other customary conditions.
- Pre-merger Chemomab equity holders will own approximately 32% of the combined company; Scipher holders will own approximately 68%.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access